One study in children with biopsy-proven NAFLD demonstrated that a reduction of 20% or more over 12 months precipitated significant improvement in serum ALT and steatosis in 68% of children [133]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.